GAP-107B8

GAP-107B8 is a novel anticancer peptide developed by PharmaGap that functions primarily as an inhibitor of protein kinase C (PKC), a signaling enzyme implicated in tumor cell growth, survival, and chemoresistance.[5][9] Preclinical studies have shown that GAP-107B8 is highly cytotoxic in vitro across a wide range of cancer cell types, including chemo‑resistant lines, and significantly reduces proliferation in multiple ovarian cancer models.[1][2][5][7][8] The agent has also demonstrated activity in colorectal and other solid tumor models, with evidence that it rapidly compromises tumor cell membranes and suppresses key malignant phenotypes such as proliferation, anchorage‑independent growth, and invasion.[7][16][17] PharmaGap has explored both original and modified peptide forms as well as liposomal formulations to enhance delivery and efficacy, and early in vivo work indicates tolerable intravenous administration and tumor‑burden reduction in ovarian cancer xenograft models, though the program has remained at the preclinical stage without reported human trials.[6][10][12][14][18]